Effects of larazotide acetate, a tight junction regulator, on the liver and intestinal damage in acute liver failure in rats.

Caliskan AR, Gul M, Yılmaz I, Otlu B, Uremis N, Uremis MM, Kilicaslan I, Gul S, Tikici D, Saglam O, Yalcin M, Demirel U, Harputluoglu M

Human & experimental toxicology18 Nov 2021Cited by 7 (Europe PMC)

PMID34791921DOI10.1177/09603271211058882PepBankPUB-34791921

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAA-induced liver failure, drinking-water larazotide lowered serum ALT versus TAA alone.
In plain wordsIn rats with liver failure, drinking-water larazotide lowered ALT compared with TAA alone.
Peptide
Larazotide
Outcome
DecreaseSerum ALT with drinking-water larazotide
Study
ratn: not reported in source
Thioacetamide-induced acute liver failure
Comparator
TAA group
Outcome group
Liver fat and liver function · Liver
Studied dose
0.01 mg/mL · oral · 7 days before TAAAs given in this study (rat).
Source sentences
Summary
Serum ALT levels in the TAA + LA(dw) group were significantly lower than in the TAA group (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
The thioacetamide (TAA) group received intraperitoneal (ip) injections of 300 mg/kg TAA for 3 days.
Summary · context
The TAA+LA(dw) (drinking water) group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of TAA.
Summary · context
The TAA + LA(g) (gavage) group received prophylactic 0.01 mg/mL LA via oral gavage for 7 days before the first dose of TAA.
Report a problemFND-3479192101
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAA-induced liver failure, drinking-water larazotide did not significantly change liver damage scores versus TAA alone.
In plain wordsIn rats with liver failure, drinking-water larazotide did not significantly change liver damage scores compared with TAA alone.
Peptide
Larazotide
Outcome
No significant changeLiver damage score with drinking-water larazotide
Study
ratn: not reported in source
Thioacetamide-induced acute liver failure
Comparator
TAA group
Outcome group
Liver fat and liver function · Liver
Studied dose
0.01 mg/mL · oral · 7 days before TAAAs given in this study (rat).
Source sentences
Summary
There was no significant difference between the TAA and TAA + LA(dw) groups and TAA and TAA + LA(g) groups for liver damage scores.
3 context sentences(design, population, supporting numbers)
Summary · context
The thioacetamide (TAA) group received intraperitoneal (ip) injections of 300 mg/kg TAA for 3 days.
Summary · context
The TAA+LA(dw) (drinking water) group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of TAA.
Summary · context
The TAA + LA(g) (gavage) group received prophylactic 0.01 mg/mL LA via oral gavage for 7 days before the first dose of TAA.
Report a problemFND-3479192104
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAA-induced liver failure, gavage larazotide did not significantly change liver damage scores versus TAA alone.
In plain wordsIn rats with liver failure, gavage larazotide did not significantly change liver damage scores compared with TAA alone.
Peptide
Larazotide
Outcome
No significant changeLiver damage score with gavage larazotide
Study
ratn: not reported in source
Thioacetamide-induced acute liver failure
Comparator
TAA group
Outcome group
Liver fat and liver function · Liver
Studied dose
0.01 mg/mL · oral gavage · 7 days before TAAAs given in this study (rat).
Source sentences
Summary
There was no significant difference between the TAA and TAA + LA(dw) groups and TAA and TAA + LA(g) groups for liver damage scores.
3 context sentences(design, population, supporting numbers)
Summary · context
The thioacetamide (TAA) group received intraperitoneal (ip) injections of 300 mg/kg TAA for 3 days.
Summary · context
The TAA+LA(dw) (drinking water) group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of TAA.
Summary · context
The TAA + LA(g) (gavage) group received prophylactic 0.01 mg/mL LA via oral gavage for 7 days before the first dose of TAA.
Report a problemFND-3479192105
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAA-induced liver failure, drinking-water larazotide significantly reduced intestinal damage scores versus TAA alone.
In plain wordsIn rats with liver failure, drinking-water larazotide reduced intestinal damage scores compared with TAA alone.
Peptide
Larazotide
Outcome
DecreaseIntestinal damage score
Study
ratn: not reported in source
Thioacetamide-induced acute liver failure
Comparator
TAA group
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.01 mg/mL · oral · 7 days before TAAAs given in this study (rat).
Source sentences
Summary
However, intestinal damage scores significantly decreased in the TAA + LA(dw) group compared to the TAA group.
3 context sentences(design, population, supporting numbers)
Summary · context
The thioacetamide (TAA) group received intraperitoneal (ip) injections of 300 mg/kg TAA for 3 days.
Summary · context
The TAA+LA(dw) (drinking water) group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of TAA.
Summary · context
The TAA + LA(g) (gavage) group received prophylactic 0.01 mg/mL LA via oral gavage for 7 days before the first dose of TAA.
Report a problemFND-3479192106
05AnimalAnimal study (in vivo)Efficacy outcome
Rats receiving TAA and drinking-water larazotide showed fusion of neighboring villus epithelial cells and epithelial bridges between villi.
In plain wordsIn rats receiving TAA and drinking-water larazotide, neighboring villi formed epithelial connections.
Peptide
Larazotide
Outcome
Not applicableEpithelial fusion and bridges
Study
ratn: not reported in source
Thioacetamide-induced acute liver failure
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.01 mg/mL · oral · 7 days before TAAAs given in this study (rat).
Source sentences
Summary
In the TAA + LA(dw) group, fusion occurred between the surface epithelial cells of neighboring villi and connecting regions formed as epithelial bridges between the villi.
3 context sentences(design, population, supporting numbers)
Summary · context
The thioacetamide (TAA) group received intraperitoneal (ip) injections of 300 mg/kg TAA for 3 days.
Summary · context
The TAA+LA(dw) (drinking water) group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of TAA.
Summary · context
The TAA + LA(g) (gavage) group received prophylactic 0.01 mg/mL LA via oral gavage for 7 days before the first dose of TAA.
Report a problemFND-3479192107

Studies that did not test the peptide alone2

In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Larazotide.

06AnimalNot a test of Larazotide aloneAnimal study (in vivo)Efficacy outcome
In rats, serum ammonia did not differ between TAA and other groups, whose identities were not specified in the result.
In plain wordsIn rats, ammonia levels did not differ between TAA and other groups, which the result did not identify.
Peptide
Larazotide
Outcome
No significant changeSerum ammonia in other groups
Study
ratn: not reported in source
Thioacetamide-induced acute liver failure
Comparator
TAA group
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
However, serum ammonia and ALT levels did not differ between the TAA and other groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The thioacetamide (TAA) group received intraperitoneal (ip) injections of 300 mg/kg TAA for 3 days.
Summary · context
The TAA+LA(dw) (drinking water) group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of TAA.
Summary · context
The TAA + LA(g) (gavage) group received prophylactic 0.01 mg/mL LA via oral gavage for 7 days before the first dose of TAA.
In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.
Report a problemFND-3479192102
07AnimalNot a test of Larazotide aloneAnimal study (in vivo)Efficacy outcome
In rats, serum ALT did not differ between TAA and other groups, whose identities were not specified in the result.
In plain wordsIn rats, ALT did not differ between TAA and other groups, which the result did not identify.
Peptide
Larazotide
Outcome
No significant changeSerum ALT in other groups
Study
ratn: not reported in source
Thioacetamide-induced acute liver failure
Comparator
TAA group
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
However, serum ammonia and ALT levels did not differ between the TAA and other groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The thioacetamide (TAA) group received intraperitoneal (ip) injections of 300 mg/kg TAA for 3 days.
Summary · context
The TAA+LA(dw) (drinking water) group received prophylactic 0.01 mg/mL LA orally for 7 days before the first dose of TAA.
Summary · context
The TAA + LA(g) (gavage) group received prophylactic 0.01 mg/mL LA via oral gavage for 7 days before the first dose of TAA.
In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.
Report a problemFND-3479192103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.